Researchers found that a new drug called naronapride significantly improves symptoms of gastroparesis, a condition that causes delayed stomach emptying and can lead to nausea, abdominal pain, and early fullness after eating. In a recent study involving 328 adults with moderate-to-severe gastroparesis, those taking either 20 mg or 40 mg doses of naronapride three times a day reported notable improvements in their symptoms compared to those on a placebo.

This finding is particularly relevant for people suffering from gastroparesis, which affects approximately 22 out of every 100,000 individuals in the U.S. and Europe. The study showed that around 15-20% more participants experienced meaningful symptom relief with naronapride compared to placebo. Improvements were observed in key symptoms like nausea and abdominal pain, which can significantly enhance quality of life for those affected by this chronic condition.

The evidence comes from a Phase 2b clinical trial, which is an early-stage study designed to assess the efficacy and safety of new treatments. While the results are promising, they are not yet definitive, as further studies are needed to confirm these findings and establish the drug’s long-term effectiveness. Naronapride has been tested in over 1,200 subjects, showing a favorable safety profile with no new safety concerns identified.

If you or someone you know struggles with gastroparesis, keep an eye on developments regarding naronapride as it moves closer to potential approval. Until then, maintaining a balanced diet and consulting with a healthcare provider about symptom management options remains crucial.

Source: globenewswire.com